AstraZeneca wins priority review schedule for leukemia drug; Penn gene therapy upstart grabs $9.29M with Frazier’s help

AstraZeneca has won a priority review for its anti-CD22 therapy moxetumomab for hairy cell leukemia. The pharma giant can now expect a decision on third-line use in the third quarter, marking another prospective advance for its critically important oncology pipeline.

→ With major help from Frazier Healthcare Partners, a stealthy gene therapy company from the University of Pennsylvania has secured $9.29 million in investment. Gene therapy pioneer James Wilson co-registered the company in 2016, the Philadelphia Inquirer notes, but has since been replaced on the board by Penn medical school vice dean Kevin Mahoney. Krishna Polu, a former CytomX chief medical officer who joined Frazier as an entrepreneur in residence, is the CEO. Several Frazier execs, including Patrick Heron and Tadataka Tamada, are also on the board.

→ Switzerland’s Glycemicon announced today that after a second closing, it has raised a total of $5.28 million (CHF 5.05 million) to advance cat and human studies of its neutraceuticals. The biotech is developing a pipeline of novel food products that manages prediabetes, the “gray area” between normal blood sugar levels and diabetes, as well as weight.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Clinical Scientist
Molecular Templates Jersey City, NJ
Manufacturing Associate - GMP Upstream
Molecular Templates Austin, TX
Director, Regulatory Affairs
Molecular Templates Jersey City, NJ
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Manufacturing Associate - GMP Downstream
Molecular Templates Austin, TX

Visit Endpoints Careers ->